These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33504193)

  • 21. Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis.
    Peng H; Tang LL; Liu X; Chen L; Li WF; Mao YP; Zhang Y; Liu LZ; Tian L; Guo Y; Sun Y; Ma J
    BMC Cancer; 2018 Mar; 18(1):323. PubMed ID: 29580204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-EGFR therapies in nasopharyngeal carcinoma.
    Chen X; Liang R; Zhu X
    Biomed Pharmacother; 2020 Nov; 131():110649. PubMed ID: 32836074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
    Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
    Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Peng H; Tang LL; Liu X; Chen L; Li WF; Mao YP; Zhang Y; Liu LZ; Tian L; Guo Y; Sun Y; Ma J
    Cancer Sci; 2018 May; 109(5):1609-1616. PubMed ID: 29575438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.
    Ramos-Suzarte M; Lorenzo-Luaces P; Lazo NG; Perez ML; Soriano JL; Gonzalez CE; Hernadez IM; Albuerne YÁ; Moreno BP; Alvarez ES; Callejo IP; Alert J; Martell JA; Gonzalez YS; Gonzalez YS; Astudillo de la Vega H; Ruiz-Garcia EB; Ramos TC
    Cancer Biol Ther; 2012 Jun; 13(8):600-5. PubMed ID: 22555809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
    Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells.
    Huang J; Yuan X; Pang Q; Zhang H; Yu J; Yang B; Zhou L; Zhang F; Liu F
    Drug Des Devel Ther; 2018; 12():2223-2231. PubMed ID: 30038488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma.
    Li HM; Li P; Qian YJ; Wu X; Xie L; Wang F; Zhang H; Liu L
    BMC Cancer; 2016 Dec; 16(1):946. PubMed ID: 27955638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience.
    Xu S; Ramos-Suzarte M; Bai X; Xu B
    Oncotarget; 2016 May; 7(22):33391-407. PubMed ID: 27050148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
    Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
    Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
    Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
    Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis.
    Zhi-Qiang W; Qi M; Ji-Bin L; Rui Y; You-Ping L; Rui S; Guang-Yuan H; Ming-Yuan C; Yi-Jun H
    BMC Cancer; 2019 Nov; 19(1):1122. PubMed ID: 31744469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].
    Han SH; Yu L; Zhang Z; Zhang PJ; Song HP; Guo CY
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):623-6. PubMed ID: 24314223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
    Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY
    Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sleep in nasopharyngeal carcinoma patients before chemotherapy, after induction chemotherapy, and after concurrent chemoradiotherapy.
    Mo Y; Zhu X; Lai X; Li L
    Med Hypotheses; 2020 Nov; 144():109840. PubMed ID: 32505065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin.
    Ramakrishnan MS; Eswaraiah A; Crombet T; Piedra P; Saurez G; Iyer H; Arvind AS
    MAbs; 2009; 1(1):41-8. PubMed ID: 20046573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction treatment prior to chemoradiotherapy in nasopharyngeal carcinoma: triplet or doublet chemotherapy?
    Hennessy MA; Morris PG
    Anticancer Drugs; 2020 Feb; 31(2):97-100. PubMed ID: 31815764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
    Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
    BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone on locally advanced nasopharyngeal carcinoma.
    Liu H; Ding XR; Song YQ; Jiang C; Zhong XM; Hui HX
    J Biol Regul Homeost Agents; 2020; 34(6):2115-2119. PubMed ID: 33191713
    [No Abstract]   [Full Text] [Related]  

  • 40. A Retrospective Study to Compare Five Induction Chemotherapy Regimens Prior to Radiotherapy in the Reduction of Regional Lymph Node Size in Patients with Nasopharyngeal Carcinoma.
    Chen J; Qi J; Yu B; Peng XH; Wang F; Tan JJ; Chen QQ; Peng XY; Zeng FF; Liu X
    Med Sci Monit; 2018 Apr; 24():2562-2568. PubMed ID: 29697098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.